Follow
Morten Mau-Sorensen
Morten Mau-Sorensen
Department of Oncology, Rigshospitalet
Verified email at dadlnet.dk
Title
Cited by
Cited by
Year
Enhanced detection of circulating tumor DNA by fragment size analysis
F Mouliere, D Chandrananda, AM Piskorz, EK Moore, J Morris, ...
Science translational medicine 10 (466), eaat4921, 2018
8082018
Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial
HSP Benedikte Hasselbalch, Ulrik Lassen, Steinbjørn Hansen, Mats Holmberg ...
Neuro-oncology 12 (5), 508-516, 2010
2682010
First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors
Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF ...
Clin Oncol 34 (34), 4142-4150, 2016
219*2016
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial
JS De Bono, N Concin, DS Hong, FC Thistlethwaite, JP Machiels, ...
The lancet oncology 20 (3), 383-393, 2019
1522019
Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up
G DAddario, E Felip, ESMO Guidelines Working Group
Annals of oncology 19 (S2), ii39-ii39, 2008
147*2008
Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma
J Kuruvilla, M Savona, R Baz, PM Mau-Sorensen, N Gabrail, R Garzon, ...
Blood, The Journal of the American Society of Hematology 129 (24), 3175-3183, 2017
1462017
A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia
R Garzon, M Savona, R Baz, M Andreeff, N Gabrail, M Gutierrez, L Savoie, ...
Blood, The Journal of the American Society of Hematology 129 (24), 3165-3174, 2017
1402017
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M Sørensen, M Pijls-Johannesma, E Felip
Annals of Oncology 21, v120-v125, 2010
1342010
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia
C Chen, D Siegel, M Gutierrez, M Jacoby, CC Hofmeister, N Gabrail, ...
Blood 131 (8), 855-863, 2018
1312018
Bevacizumab plus irinotecan in the treatment of patients with progressive recurrent malignant brain tumours
HS Poulsen, K Grunnet, M Sorensen, P Olsen, B Hasselbalch, ...
Acta Oncologica 48, 52-58, 2009
1302009
In vitro cross-resistance and collateral sensitivity in seven resistant small cell lung cancer cell lines. Preclinical identification of suitable drug partners to taxotere …
PB Jensen, B Holm, M Sorensen, IJ Christensen, M Sehested
Br j Cancer 75, 869-877, 1997
1301997
Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
KG Spindler, AK Boysen, N Pallisgård, JS Johansen, J Tabernero, ...
the oncologist 22 (9), 1049-1055, 2017
1202017
Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up
G D'addario, E Felip
Annals of oncology 19 (suppl_2), ii39-ii40, 2008
1122008
Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme
U Lassen, M Sorensen, TB Gaziel, B Hasselbalch, HS Poulsen
Anticancer Research 33, 1657-1660, 2013
1112013
Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer
LM Smyth, SA Piha-Paul, HH Won, AM Schram, C Saura, S Loi, J Lu, ...
Cancer discovery 10 (2), 198-213, 2020
1072020
Abstract CT127: Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi)
D Hyman, S Kummar, A Farago, B Geoerger, M Mau-Sorensen, M Taylor, ...
Cancer Research 79 (13_Supplement), CT127-CT127, 2019
1032019
A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients …
U Lassen, LR Molife, M Sorensen, SA Engelholm, L Vidal, R Sinha, ...
Br J Cancer, 29 (1), 12-17, 2010
962010
Immunohistochemical detection of DNA topoisomerase II , P-glyco-protein and MultiDrug Resistance related protein (MRP) in small cell and non-small cell lung cancer
J Kreisholt, M Sorensen, PB Jensen, BS Nielsen, CB Andersen, ...
br j cancer 77, 1469-1473, 1998
93*1998
Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum-resistant ovarian cancer
Y Chen, SC Camacho, TR Silvers, ARA Razak, NY Gabrail, JF Gerecitano, ...
Clinical Cancer Research 23 (6), 1552-1563, 2017
822017
Inhibition of the nuclear export receptor XPO1 as a therapeutic target for platinum resistant ovarian cancer
Y Chen, C Camacho, TR Silvers, AR Razak, JF Gabrail, NY, Gerecitano, ...
Clin Cancer Res 23, 1552-1563, 2017
822017
The system can't perform the operation now. Try again later.
Articles 1–20